A snapshot of Plasmodium falciparum malaria drug resistance markers in Sudan: a pilot study

BMC Res Notes. 2020 Nov 7;13(1):512. doi: 10.1186/s13104-020-05363-0.

Abstract

Objectives: Malaria infection is still known to be a worldwide public health problem, especially in tropical and sub-tropical African countries like Sudan. A pilot study conducted to describe the trend of P. falciparum drug resistance markers in 2017-2018 in comparison to CQ and AS/SP eras in Sudan. The Pfcrt, Pfmdr-1, Pfdhfr, and Pfdhps genes were investigated. Data deposited by the worldwide antimalarial resistance network was consulted, and the molecular markers previously reported from Sudan were analyzed.

Results: Drug molecular markers analysis was successfully done on 20 P. falciparum isolates. The Pfcrt K76 showed high frequency; 16 (80%). For the Pfmdr-1, 9 (45%) isolates were carrying the N86 allele, and 11 (55%) were 86Y allele. While the Y184F of the Pfmdr-1 showed a higher frequency of 184F compared to Y184; 16 (80%) and 4 (20%), respectively. In the Pfdhfr, 51I allele showed higher frequency compared to N51; 18 (90%) and 2 (10%), respectively. For S108N, 18 (90%) were 108 N and 2 (10%) were S108. In the Pfdhps, all isolates were carrying the mutant alleles; 437G and 540E. The frequency distribution of the Pfcrt, Pfmdr-1, Pfdhfr, Pfdhps was significantly different across the whole years in Sudan.

Keywords: Molecular markers; Multi drug resistance; Plasmodium falciparum; Sudan.

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Drug Combinations
  • Drug Resistance / genetics
  • Humans
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / epidemiology
  • Pilot Projects
  • Plasmodium falciparum / genetics
  • Protozoan Proteins / genetics
  • Pyrimethamine / therapeutic use
  • Sudan
  • Sulfadoxine / therapeutic use

Substances

  • Antimalarials
  • Drug Combinations
  • Protozoan Proteins
  • Sulfadoxine
  • Pyrimethamine